Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B L Weber

Showing results (91-100 of 115) with videos related to

Pageof 12
Sort By:
Genes, Chromosomes & Cancer|June 22, 2000
An Alu-mediated 7.1 kb deletion of BRCA1 exons 8 and 9 in breast and ovarian cancer families that results in alternative splicing of exon 10E M Rohlfs, N Puget, M L Graham, et al.
American Journal of Human Genetics|January 1, 1995
An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage ConsortiumS A Narod, D Ford, P Devilee, et al.
Nature Genetics|April 1, 1995
Somatic mutations in the BRCA1 gene in sporadic ovarian tumoursS D Merajver, T M Pham, R F Caduff, et al.
Molecular Cell|October 17, 1998
Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cellsJ Chen, D P Silver, D Walpita, et al.
Oncogene|June 19, 1997
Relationship of p215BRCA1 to tyrosine kinase signaling pathways and the cell cycle in normal and transformed cellsH T Zhang, X Zhang, H Z Zhao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatmentM D Pegram, A Lipton, D F Hayes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2001
Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinicA M Martin, M A Blackwood, D Antin-Ozerkis, et al.
The New England Journal of Medicine|November 7, 1996
Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1S C Rubin, I Benjamin, K Behbakht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1997
Breast conservation and prolonged chemotherapy for locally advanced breast cancer: the University of Michigan experienceS D Merajver, B L Weber, R Cody, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2000
Anticipated versus actual emotional reactions to disclosure of results of genetic tests for cancer susceptibility: findings from p53 and BRCA1 testing programsM Dorval, A F Patenaude, K A Schneider, et al.
Pageof 12

Showing results (91-100 of 115) with videos related to

Sort By:
Pageof 12
Genes, Chromosomes & Cancer|June 22, 2000
An Alu-mediated 7.1 kb deletion of BRCA1 exons 8 and 9 in breast and ovarian cancer families that results in alternative splicing of exon 10E M Rohlfs, N Puget, M L Graham, et al.
American Journal of Human Genetics|January 1, 1995
An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage ConsortiumS A Narod, D Ford, P Devilee, et al.
Nature Genetics|April 1, 1995
Somatic mutations in the BRCA1 gene in sporadic ovarian tumoursS D Merajver, T M Pham, R F Caduff, et al.
Molecular Cell|October 17, 1998
Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cellsJ Chen, D P Silver, D Walpita, et al.
Oncogene|June 19, 1997
Relationship of p215BRCA1 to tyrosine kinase signaling pathways and the cell cycle in normal and transformed cellsH T Zhang, X Zhang, H Z Zhao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatmentM D Pegram, A Lipton, D F Hayes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2001
Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinicA M Martin, M A Blackwood, D Antin-Ozerkis, et al.
The New England Journal of Medicine|November 7, 1996
Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1S C Rubin, I Benjamin, K Behbakht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1997
Breast conservation and prolonged chemotherapy for locally advanced breast cancer: the University of Michigan experienceS D Merajver, B L Weber, R Cody, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2000
Anticipated versus actual emotional reactions to disclosure of results of genetic tests for cancer susceptibility: findings from p53 and BRCA1 testing programsM Dorval, A F Patenaude, K A Schneider, et al.
Pageof 12